季节性流感疫苗免疫期内免疫力衰减的系统综述与Meta分析
该系统综述与Meta分析检索评估季节性流感疫苗免疫原性的III/IV期随机临床试验,共纳入10项定性合成、7项定量分析(儿童3项、老年人4项)。多数研究显示抗体滴度在接种后1个月上升、6个月下降;6个月时儿童佐剂疫苗较标准疫苗的血清保护率风险差显著更高(0.29;95%CI 0.14-0.44)。结论认为流感疫苗在整个流感季节可持续提供抗体应答,即使6个月内应答衰减,接种仍可能提供显著保护优势,佐剂疫苗可能增强该优势,尤其儿童。
要点
- 多数纳入研究显示接种后1个月抗体滴度上升、6个月下降。
- 6个月时儿童佐剂疫苗较标准疫苗血清保护率风险差显著更高(0.29;95%CI 0.14-0.44)。
- 老年人佐剂疫苗较标准疫苗血清保护率略有升高且6个月内保持稳定。
核心结论
- 流感疫苗接种后在整个典型流感季节可持续检测到抗体应答;即使6个月内应答衰减,接种仍可能提供显著保护优势,佐剂疫苗可能增强该优势,尤其儿童;需进一步研究确定抗体应答下降的确切起始时间以更好指导流感疫苗接种项目的最佳时机。
研究设计与样本
- 系统检索电子数据库与临床试验注册库,纳入评估6月龄及以上健康人群季节性流感疫苗免疫原性(血凝抑制试验测定)的III/IV期随机临床试验。
- 共识别1918篇文章,10项纳入定性合成,7项纳入定量分析(儿童3项、老年人4项)。
- 除一项因结局数据缺失评为高偏倚风险外,其余研究均评为低偏倚风险。
主要发现
- 多数纳入研究发现抗体滴度在接种后1个月上升、6个月下降。
- 接种后6个月,儿童佐剂疫苗较标准疫苗的血清保护率总体风险差显著更高(0.29;95%CI 0.14-0.44)。
- 老年人佐剂疫苗较标准疫苗的血清保护率略有升高,且6个月内保持稳定(接种前:0.03;95%CI 0.00-0.09;接种后1个月和6个月:0.05;95%CI 0.01-0.09)。
局限性
- 一项研究因结局数据缺失被评为高偏倚风险。
- 需进一步研究确定抗体应答下降的确切起始时间,以更好指导流感疫苗接种项目的最佳时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, studies have suggested that influenza antibody titers decline with time since vaccination. Duration of vaccine protection is an important factor to determine the optimal timing of vaccination. OBJECTIVE: We aimed to systematically evaluate the implication of waning immunity on the duration of seasonal influenza vaccine antibody response. METHOD: Electronic databases and clinical trial registries were systematically searched to identify phase III/IV randomized clinical trials evaluating the immunogenicity of seasonal influenza vaccines measured by hemagglutination inhibition assay in healthy individuals six months of age and older. Meta-analyses were conducted to compare adjuvanted and standard influenza vaccine responses with time since vaccination. RESULTS: 1918 articles were identified, of which ten were included in qualitative synthesis and seven in quantitative analysis (children; n=3, older adults; n=4). All studies were deemed to be at low risk of bias, except one study deemed at high risk of bias due to missing outcome data. The majority of included studies found a rise in antibody titers at one-month followed by a decline at six-month post-vaccination. At six-months post-vaccination overall risk differences in seroprotection were significantly higher for children vaccinated with adjuvanted compared to standard vaccines (0.29; 95 % confidence interval (CI), 0.14-0.44). A small increase in seroprotection levels was observed among older adults vaccinated with an adjuvanted compared to standard vaccines, which remained constant over six-months (pre-vaccination: 0.03; 95 % CI, 0.00-0.09 and one- and six-months post-vaccination: 0.05; 95 % CI, 0.01-0.09). CONCLUSIONS: Our results found evidence of persistent antibody responses following influenza vaccination over the course of a typical influenza season. Even if influenza vaccine responses wane over a six-month period, vaccination likely still provides a significant advantage in protection, which may be enhanced with adjuvanted vaccines, particularly in children. Further research is needed to identify the exact timing when the decline in antibody response begins to better inform the optimal timing of influenza vaccination programs. TRIAL REGISTRATION: PROSPERO (CRD42019138585).
引用
- Doyon-Plourde P, Przepiorkowski J, Young K, et al. Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis. Vaccine. 2023. PMID: 37331840. doi:10.1016/j.vaccine.2023.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。